Antidiabetic effect of gemigliptin: a systematic review and meta-analysis of randomized controlled trials with Bayesian inference through a quality management system
出版年份 2021 全文链接
标题
Antidiabetic effect of gemigliptin: a systematic review and meta-analysis of randomized controlled trials with Bayesian inference through a quality management system
作者
关键词
-
出版物
Scientific Reports
Volume 11, Issue 1, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2021-10-22
DOI
10.1038/s41598-021-00418-z
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Comparison of Gemigliptin and Dapagliflozin Effects on Glycemic Variability in Type 2 Diabetes: A Randomized, Open‐Label, Active‐Controlled, 12‐Week Study (STABLE II Study)
- (2019) Soo Heon Kwak et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety of gemigliptin as add‐on therapy to insulin, with or without metformin, in patients with type 2 diabetes mellitus (ZEUS II study)
- (2019) Young Min Cho et al. DIABETES OBESITY & METABOLISM
- Effect of vegetarian dietary patterns on cardiometabolic risk factors in diabetes: A systematic review and meta-analysis of randomized controlled trials
- (2018) Effie Viguiliouk et al. CLINICAL NUTRITION
- A 52-week extension study of switching from gemigliptin vs sitagliptin to gemigliptin only as add-on therapy for patients with type 2 diabetes who are inadequately controlled with metformin alone
- (2018) Chan-Hee Jung et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety of initial combination therapy with gemigliptin and metformin compared with monotherapy with either drug in patients with type 2 diabetes: A double-blind randomized controlled trial (INICOM study)
- (2016) Soo Lim et al. DIABETES OBESITY & METABOLISM
- Pharmacological profiles of gemigliptin (LC15-0444), a novel dipeptidyl peptidase-4 inhibitor, in vitro and in vivo
- (2016) Sung-Ho Kim et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Gemigliptin: An Update of Its Clinical Use in the Management of Type 2 Diabetes Mellitus
- (2016) Sung-Ho Kim et al. Diabetes & Metabolism Journal
- Gemigliptin improves renal function and attenuates podocyte injury in mice with diabetic nephropathy
- (2015) Eunsoo Jung et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Improving the error rates of the Begg and Mazumdar test for publication bias in fixed effects meta-analysis
- (2014) Miriam Gjerdevik et al. BMC Medical Research Methodology
- Effect of renal impairment and haemodialysis on the pharmacokinetics of gemigliptin (LC15-0444)
- (2014) J.H. Shon et al. DIABETES OBESITY & METABOLISM
- The pharmacokinetic considerations and adverse effects of DDP-4 inhibitors
- (2014) Theodosios D Filippatos et al. Expert Opinion on Drug Metabolism & Toxicology
- Effects of food on the pharmacokinetics of gemigliptin/metformin sustained-release 50/1,000 mg (25/500 mg à 2 tablets) fixeddose combination tablet in healthy male volunteers
- (2014) Hee Youn Choi et al. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
- Comparison of Weight Loss Among Named Diet Programs in Overweight and Obese Adults
- (2014) Bradley C. Johnston et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Gemigliptin, a novel dipeptidyl peptidase 4 inhibitor: first new anti-diabetic drug in the history of Korean pharmaceutical industry
- (2013) Sung-Ho Kim et al. ARCHIVES OF PHARMACAL RESEARCH
- Efficacy and safety of the dipeptidyl peptidase-4 inhibitor gemigliptin compared with sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone
- (2013) E. J. Rhee et al. DIABETES OBESITY & METABOLISM
- Effects of Ketoconazole and Rifampicin on the Pharmacokinetics of Gemigliptin, a Dipeptidyl Peptidase-IV Inhibitor: A Crossover Drug–Drug Interaction Study in Healthy Male Korean Volunteers
- (2012) Yook-Hwan Noh et al. CLINICAL THERAPEUTICS
- A multicentre, multinational, randomized, placebo-controlled, double-blind, phase 3 trial to evaluate the efficacy and safety of gemigliptin (LC15-0444) in patients with type 2 diabetes
- (2012) S. J. Yang et al. DIABETES OBESITY & METABOLISM
- A multicenter, randomized, placebo-controlled, double-blind phase II trial evaluating the optimal dose, efficacy and safety of LC 15-0444 in patients with type 2 diabetes
- (2010) E. J. Rhee et al. DIABETES OBESITY & METABOLISM
- Pharmacokinetics and pharmacodynamics of LC15-0444, a novel dipeptidyl peptidase IV inhibitor, after multiple dosing in healthy volunteers
- (2009) Kyoung Soo Lim et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started